Industrial Materials
Compare Stocks
4 / 10Stock Comparison
CRMLW vs CRIS vs MP vs TGTX
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Industrial Materials
Biotechnology
CRMLW vs CRIS vs MP vs TGTX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Industrial Materials | Biotechnology | Industrial Materials | Biotechnology |
| Market Cap | $437M | $76M | $12.28B | $6.87B |
| Revenue (TTM) | — | $9M | $305M | $700M |
| Net Income (TTM) | $-147M | $-8M | $-71M | $462M |
| Gross Margin | — | 99.5% | 8.3% | 83.0% |
| Operating Margin | — | -348.4% | -36.4% | 21.3% |
| Forward P/E | — | — | 274.3x | 32.3x |
| Total Debt | $19M | $2M | $1.04B | $261M |
| Cash & Equiv. | $1M | $5M | $1.17B | $79M |
CRMLW vs CRIS vs MP vs TGTX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Feb 24 | May 26 | Return |
|---|---|---|---|
| Critical Metals Cor… (CRMLW) | 100 | 5454.5 | +5354.5% |
| Curis, Inc. (CRIS) | 100 | 5.7 | -94.3% |
| MP Materials Corp. (MP) | 100 | 454.5 | +354.5% |
| TG Therapeutics, In… (TGTX) | 100 | 249.9 | +149.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CRMLW vs CRIS vs MP vs TGTX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CRMLW is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 42.3% 10Y total return vs MP's 5.9%
- +23.5% vs CRIS's -72.0%
CRIS plays a supporting role in this comparison — it may shine differently against other peers.
MP lags the leaders in this set but could rank higher in a more targeted comparison.
TGTX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 0.77
- Rev growth 87.3%, EPS growth 17.5%, 3Y rev CAGR 5.0%
- Lower volatility, beta 0.77, Low D/E 40.2%, current ratio 4.10x
- Beta 0.77, current ratio 4.10x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 87.3% revenue growth vs CRIS's -13.4% | |
| Value | Lower P/E (32.3x vs 274.3x) | |
| Quality / Margins | 66.0% margin vs CRIS's -80.3% | |
| Stability / Safety | Beta 0.77 vs CRMLW's 2.96 | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +23.5% vs CRIS's -72.0% | |
| Efficiency (ROA) | 42.8% ROA vs CRMLW's -312.7%, ROIC 16.4% vs -14.6% |
CRMLW vs CRIS vs MP vs TGTX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
CRMLW vs CRIS vs MP vs TGTX — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
TGTX leads in 3 of 6 categories
MP leads 1 • CRMLW leads 1 • CRIS leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
TGTX leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TGTX is the larger business by revenue, generating $700M annually — 74.2x CRIS's $9M. TGTX is the more profitable business, keeping 66.0% of every revenue dollar as net income compared to CRIS's -80.3%. On growth, TGTX holds the edge at +69.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | — | $9M | $305M | $700M |
| EBITDAEarnings before interest/tax | — | -$33M | -$43M | $150M |
| Net IncomeAfter-tax profit | — | -$8M | -$71M | $462M |
| Free Cash FlowCash after capex | — | -$27M | -$314M | -$14M |
| Gross MarginGross profit ÷ Revenue | — | +99.5% | +8.3% | +83.0% |
| Operating MarginEBIT ÷ Revenue | — | -3.5% | -36.4% | +21.3% |
| Net MarginNet income ÷ Revenue | — | -80.3% | -23.3% | +66.0% |
| FCF MarginFCF ÷ Revenue | — | -2.9% | -102.8% | -2.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -66.0% | +49.1% | +69.6% |
| EPS Growth (YoY)Latest quarter vs prior year | — | +198.4% | +121.4% | +2.9% |
Valuation Metrics
MP leads this category, winning 2 of 4 comparable metrics.
Valuation Metrics
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $437M | $76M | $12.3B | $6.9B |
| Enterprise ValueMkt cap + debt − cash | $455M | $73M | $12.2B | $7.1B |
| Trailing P/EPrice ÷ TTM EPS | -2.97x | -0.99x | -138.26x | 15.53x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 274.33x | 32.25x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | 57.07x |
| Price / SalesMarket cap ÷ Revenue | — | 8.04x | 44.59x | 11.15x |
| Price / BookPrice ÷ Book value/share | — | 13.91x | 4.92x | 10.72x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
Profitability & Efficiency
TGTX leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
TGTX delivers a 87.4% return on equity — every $100 of shareholder capital generates $87 in annual profit, vs $-23 for CRMLW. CRIS carries lower financial leverage with a 0.30x debt-to-equity ratio, signaling a more conservative balance sheet compared to MP's 0.44x. On the Piotroski fundamental quality scale (0–9), MP scores 4/9 vs CRMLW's 1/9, reflecting mixed financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -23.3% | -138.8% | -3.7% | +87.4% |
| ROA (TTM)Return on assets | -3.1% | -26.1% | -2.0% | +42.8% |
| ROICReturn on invested capital | -14.6% | — | -4.7% | +16.4% |
| ROCEReturn on capital employed | -21.7% | -2.3% | -4.2% | +17.7% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 3 | 4 | 4 |
| Debt / EquityFinancial leverage | — | 0.30x | 0.44x | 0.40x |
| Net DebtTotal debt minus cash | $18M | -$3M | -$123M | $182M |
| Cash & Equiv.Liquid assets | $1M | $5M | $1.2B | $79M |
| Total DebtShort + long-term debt | $19M | $2M | $1.0B | $261M |
| Interest CoverageEBIT ÷ Interest expense | -0.08x | -107.35x | -2.80x | 5.67x |
Total Returns (Dividends Reinvested)
CRMLW leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CRMLW five years ago would be worth $432,693 today (with dividends reinvested), compared to $28 for CRIS. Over the past 12 months, CRMLW leads with a +2353.4% total return vs CRIS's -72.0%. The 3-year compound annual growth rate (CAGR) favors CRMLW at 2.5% vs CRIS's -67.0% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +97.8% | -41.1% | +25.8% | +46.9% |
| 1-Year ReturnPast 12 months | +2353.4% | -72.0% | +192.7% | +23.5% |
| 3-Year ReturnCumulative with dividends | +4226.9% | -96.4% | +221.7% | +30.0% |
| 5-Year ReturnCumulative with dividends | +4226.9% | -99.7% | +149.7% | +7.0% |
| 10-Year ReturnCumulative with dividends | +4226.9% | -99.7% | +591.3% | +436.5% |
| CAGR (3Y)Annualised 3-year return | +2.5% | -67.0% | +47.6% | +9.1% |
Risk & Volatility
TGTX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
TGTX is the less volatile stock with a 0.77 beta — it tends to amplify market swings less than CRMLW's 2.96 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TGTX currently trades 97.8% from its 52-week high vs CRIS's 18.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.96x | 1.87x | 1.40x | 0.77x |
| 52-Week HighHighest price in past year | $20.73 | $3.13 | $100.25 | $44.00 |
| 52-Week LowLowest price in past year | $0.17 | $0.49 | $18.64 | $25.28 |
| % of 52W HighCurrent price vs 52-week peak | +26.0% | +18.4% | +69.0% | +97.8% |
| RSI (14)Momentum oscillator 0–100 | 56.6 | 48.9 | 66.8 | 74.2 |
| Avg Volume (50D)Average daily shares traded | 47K | 444K | 5.6M | 2.1M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: MP as "Buy", TGTX as "Buy". Consensus price targets imply 13.2% upside for MP (target: $78) vs -9.4% for TGTX (target: $39).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | Buy | Buy |
| Price TargetConsensus 12-month target | — | — | $78.25 | $39.00 |
| # AnalystsCovering analysts | — | — | 11 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | 0 |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +1.3% |
TGTX leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MP leads in 1 (Valuation Metrics).
CRMLW vs CRIS vs MP vs TGTX: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CRMLW or CRIS or MP or TGTX a better buy right now?
For growth investors, TG Therapeutics, Inc.
(TGTX) is the stronger pick with 87. 3% revenue growth year-over-year, versus -13. 4% for Curis, Inc. (CRIS). TG Therapeutics, Inc. (TGTX) offers the better valuation at 15. 5x trailing P/E (32. 3x forward), making it the more compelling value choice. Analysts rate MP Materials Corp. (MP) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CRMLW or CRIS or MP or TGTX?
On forward P/E, TG Therapeutics, Inc.
is actually cheaper at 32. 3x.
03Which is the better long-term investment — CRMLW or CRIS or MP or TGTX?
Over the past 5 years, Critical Metals Corp.
(CRMLW) delivered a total return of +42. 3%, compared to -99. 7% for Curis, Inc. (CRIS). Over 10 years, the gap is even starker: CRMLW returned +42. 3% versus CRIS's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CRMLW or CRIS or MP or TGTX?
By beta (market sensitivity over 5 years), TG Therapeutics, Inc.
(TGTX) is the lower-risk stock at 0. 77β versus Critical Metals Corp. 's 2. 96β — meaning CRMLW is approximately 283% more volatile than TGTX relative to the S&P 500. On balance sheet safety, Curis, Inc. (CRIS) carries a lower debt/equity ratio of 30% versus 44% for MP Materials Corp. — giving it more financial flexibility in a downturn.
05Which is growing faster — CRMLW or CRIS or MP or TGTX?
By revenue growth (latest reported year), TG Therapeutics, Inc.
(TGTX) is pulling ahead at 87. 3% versus -13. 4% for Curis, Inc. (CRIS). On earnings-per-share growth, the picture is similar: TG Therapeutics, Inc. grew EPS 1747% year-over-year, compared to -154. 6% for Critical Metals Corp.. Over a 3-year CAGR, TGTX leads at 504. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CRMLW or CRIS or MP or TGTX?
TG Therapeutics, Inc.
(TGTX) is the more profitable company, earning 72. 6% net margin versus -80. 3% for Curis, Inc. — meaning it keeps 72. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TGTX leads at 20. 0% versus -348. 4% for CRIS. At the gross margin level — before operating expenses — CRIS leads at 99. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CRMLW or CRIS or MP or TGTX more undervalued right now?
On forward earnings alone, TG Therapeutics, Inc.
(TGTX) trades at 32. 3x forward P/E versus 274. 3x for MP Materials Corp. — 242. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MP: 13. 2% to $78. 25.
08Which pays a better dividend — CRMLW or CRIS or MP or TGTX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is CRMLW or CRIS or MP or TGTX better for a retirement portfolio?
For long-horizon retirement investors, TG Therapeutics, Inc.
(TGTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 77), +436. 5% 10Y return). Critical Metals Corp. (CRMLW) carries a higher beta of 2. 96 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TGTX: +436. 5%, CRMLW: +42. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CRMLW and CRIS and MP and TGTX?
These companies operate in different sectors (CRMLW (Basic Materials) and CRIS (Healthcare) and MP (Basic Materials) and TGTX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: CRMLW is a small-cap quality compounder stock; CRIS is a small-cap quality compounder stock; MP is a mid-cap high-growth stock; TGTX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.